Sexual Health & Hormonal ResearchModerate Evidence
Kisspeptin-10
Neuropeptide that activates GnRH release from hypothalamus. Studied in hypogonadotropic hypogonadism, sexual arousal, and reproductive axis regulation research.
Kisspeptin-10 is the shortest of the naturally occurring kisspeptin peptides, consisting of 10 amino acids. Kisspeptins are key regulators of the reproductive hormonal axis. They act on the hypothalamus to stimulate GnRH (gonadotropin-releasing hormone) release, which in turn drives LH, FSH, and ultimately sex hormone production. Kisspeptin-10 has been studied in reproductive medicine and neuroendocrine research.
Reproductive Hormone Research
Kisspeptin-10 has been used extensively in human research to study the reproductive hormone axis. IV and intranasal kisspeptin-10 reliably stimulates LH and FSH pulses, making it a useful tool for studying hypothalamic function and reproductive endocrinology.
Fertility Applications
Because kisspeptin stimulates the LH surge that triggers ovulation, researchers have studied kisspeptin-10 as a trigger for ovulation in IVF protocols. Phase 2 trials showed it can trigger oocyte maturation effectively while having a potentially lower risk of ovarian hyperstimulation syndrome than HCG.
Hypogonadotropic Hypogonadism
Kisspeptin has been studied as a potential treatment for conditions where the hypothalamus is not producing enough GnRH signal. Research has examined whether kisspeptin administration can restore reproductive hormone output in these cases.
Reliably stimulates LH and FSH release in human research subjects.
Phase 2 IVF trials show it can effectively trigger oocyte maturation as an alternative to HCG.
Potential advantage over HCG trigger in reducing ovarian hyperstimulation syndrome risk.
Useful research tool for studying reproductive hormone axis in health and disease.
Kisspeptin-10 has a very short half-life, which limits sustained stimulation and requires careful dosing timing. It is not FDA-approved for any reproductive indication. Larger trials confirming its advantages over HCG as an IVF trigger are needed. Off-label and research use outside of fertility medicine contexts lacks an established evidence base.
The reproductive hormone system works like a chain of command. At the top, the hypothalamus releases GnRH in pulses, which tells the pituitary to release LH and FSH. LH and FSH then tell the ovaries or testes to produce sex hormones and support reproduction. Kisspeptin is a key upstream regulator — it sends the signal to the hypothalamus to produce GnRH. Kisspeptin-10 is the smallest active fragment of kisspeptin that retains full activity at the kisspeptin receptor. Giving kisspeptin-10 effectively activates the top of this chain, triggering a cascade of hormone releases down the line. In IVF research, timed kisspeptin-10 administration has been studied as a way to trigger the ovulation process at a precise moment.
In human research studies, kisspeptin-10 was generally well-tolerated. Its very short half-life limits sustained effects. Nausea has been reported in some participants. It is not FDA-approved. Research use in the context of reproductive hormone manipulation should account for its effects on the full reproductive hormonal axis.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
1–10nmol/kg bolus; 10nmol/min infusion in clinical studies
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Kisspeptin-10 Stimulates LH and FSH Release in Healthy Men and Women
Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes
Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy
Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.